Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of VCT220 with Rifampin or Itraconazole in Healthy Subjects
NCT07056842Phase 1Completed
- Sponsor
- Vincentage Pharma Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of VCT220 in obesity (2 cohorts), sponsored by Vincentage Pharma Co., Ltd. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity at 72 hours and Maximum observed plasma concentration at 72 hours. Started Jul 2025; status: completed.
02
Drugs
VCT220
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07056842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07056842.